The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Prelude Therapeutics Inc shares valued at $69,250 were purchased by Combs Andrew on Mar 25 ’25. At $0.69 per share, Combs Andrew acquired 100,000 shares. The insider’s holdings grew to 480,123 shares worth approximately $0.41 million following the completion of this transaction.
Also, Vaddi Krishna purchased 675,000 shares, netting a total of over 467,438 in proceeds. Following the buying of shares at $0.69 each, the insider now holds 1,999,296 shares.
Before that, Vaddi Krishna had added 15,000 shares to its account. In a trade valued at $10,959, the CEO bought Prelude Therapeutics Inc shares for $0.73 each. Upon closing the transaction, the insider’s holdings increased to 15,000 shares, worth approximately $1.14 million.
As published in a research note from H.C. Wainwright on September 19, 2024, Prelude Therapeutics Inc [PRLD] has been rated up from a Neutral to a Buy and the price target has been revised to $5. Analysts at Barclays downgraded the stock from ‘”an Equal weight”‘ to ‘”an Underweight”‘ outlook in a report released in mid June. As of March 13, 2024, JMP Securities has initiated its “Mkt outperform” rating for PRLD. Earlier on February 20, 2024, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for PRLD stock which previously was a “a Buy”.
Analyzing PRLD Stock Performance
On last trading session,, Prelude Therapeutics Inc [NASDAQ: PRLD] plunged -7.16% to $0.86. During the last five days, there has been a drop of approximately -21.36%. Over the course of the year, Prelude Therapeutics Inc shares have dropped approximately -32.46%. Shares of the company reached a 52-week high of $1.4300 on 01/06/25 and a 52-week low of $0.6101 on 04/09/25.
Support And Resistance Levels for Prelude Therapeutics Inc (PRLD)
According to the 24-hour chart, there is a support level at 0.8204, which, if violated, would cause prices to drop to 0.7797. In the upper region, resistance lies at 0.9259. The next price resistance is at 0.9907. RSI (Relative Strength Index) is 43.89 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Prelude Therapeutics Inc (PRLD)?
In terms of Prelude Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6 in the next 12 months, up nearly 545.16% from the previous closing price of $0.93. Analysts anticipate Prelude Therapeutics Inc stock to reach 10 by 2025, with the lowest price target being 3. In spite of this, 2 analysts ranked Prelude Therapeutics Inc stock as Sell at the end of 2025. On December 19, 2023, Morgan Stanley assigned a price target of “an Underweight” to the stock and downgraded coverage with a $4.
